Clinical efficacy and safety analysis of human interferonα-2b atomized inhalation combined with budesonide in the treatment of infantile bronchitis

Objective To explore the method of budesonide combined with recombinant human interferon α-2 b(rhIFNα-2 b) aerosol inhalation in children with bronchiolitis, and to observe its clinical efficacy and safety analysis, so as to provide theoretical basis for the diagnosis and treatment of children with bronchiolitis. Methods A total of 205 children with bronchiolitis admitted to Fuyang women's and children's Hospital from January to December 2018 were randomly divided into treatment group(103 cases) and control group(102 cases). The control group was treated with inhaled budesonide; the treatment group was treated with rhIFNα-2 b 200 000 IU/(kg·time) on the basis of the control group, and the two groups were given appropriate symptomatic support treatment. The clinical symptom scores of the two groups before and 7 days after treatment were dynamically observed, the improvement rate of each clinical performance was recorded, and the therapeutic effects of the two groups were compared. Results The score of asthmatic suffocation in the treatment group was significantly lower than that in the control group on the 5 th to 7 th day(P<0.05). The score of cough and wheezing in the treatment group was significantly lower than that in the control group on the 4 th to 7 th day(P<0.05). The score of three concave signs in the treatment group was significantly lower than that in the control group on the 2 nd to 5 th day(P<0.05). The score of four concave signs in the treatment group was significantly lower than that in the control group on the 4 th to 7 th day(P<0.05). The difference was statistically significant(P<0.05) d. The improvement of cough, wheezing and wheezing sound in the treatment group was significantly higher than that in the control group, the difference was statistically significant(P<0.05). On the 7 th day of treatment, the total improvement of the treatment group was higher than that of the control group[(95.68±18.71) scores vs.(76.57±21.73) scores], the difference was statistically significant(t=6.750, P<0.001), no serious adverse reactions occurred in the two groups. Conclusion Budesonide combined with rhIFNα-2 b aerosol inhalation can significantly improve the therapeutic effect of bronchiolitis in children, rapidly improve the clinical symptoms, and has high safety, which is worthy of clinical promotion.